The bar isn't set very high by the current treatme
Post# of 72440
(Total Views: 165)
Posted On: 01/17/2017 2:36:28 PM
Re: NotRichYet2 #30427
The bar isn't set very high by the current treatment. J&J's Remicade is the leader in the UC market with $2B in annual sales.
Only 39% of patients had clinical remission comparing to 15% in the placebo group. B-UP in comparison, 100% of the first four patients had clinical remission (3 with 50% reduction and 1 with 100% reduction).
https://www.remicadehcp.com/ulcerative-coliti...-remission
Remicade's patent will expire in 2018. Hello J&J!
Only 39% of patients had clinical remission comparing to 15% in the placebo group. B-UP in comparison, 100% of the first four patients had clinical remission (3 with 50% reduction and 1 with 100% reduction).
https://www.remicadehcp.com/ulcerative-coliti...-remission
Remicade's patent will expire in 2018. Hello J&J!
Quote:
What is left out of that "every patient in this trial has benefited from their Brilacidin treatment" which has my motor running on this is HOW it compares to current treatments.
(3)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼